Amylin: the hormone behind the next weight-loss wave
Last updated: October 27, 2026 · 7 min read · By the Grey Peptides Editorial Board
- Amylin is a hormone released with insulin that slows the stomach and blunts glucagon after meals. Pramlintide, the first amylin drug, was approved for diabetes in 2005 and is now listed as discontinued.
- Four newer programs aim at weight loss: cagrilintide (and CagriSema with semaglutide), petrelintide, eloralintide and amycretin. As of October 27, 2026, none is approved; CagriSema was submitted to the FDA in December 2025.
- The trial numbers differ by design: alone, the amylin drugs cut weight by about 6% to 20% over 26 to 48 weeks; combined with a GLP-1, or built into one molecule with it, the figures reach 20% to 24%.
What amylin does
Amylin is a peptide hormone released with insulin by the pancreas's beta cells, and it slows the emptying of the stomach 1. It also holds back glucagon, the hormone that raises blood sugar: in a crossover study in 14 men with type 1 diabetes, the amylin analogue pramlintide lowered mean daytime glucose from 10.2 to 8.3 mmol/L and blunted the rise of glucose and glucagon after meals, with insulin levels unchanged 2.
Natural amylin is a poor drug: it readily clumps into amyloid fibrils, and pramlintide, the analogue that reached the market, needs three injections a day because of its short half-life. Cagrilintide's design paper, by Novo Nordisk scientists, describes a stable, lipidated, long-acting analogue built to get past both 3. They also act on more than one receptor. Amylin receptors are built from the calcitonin receptor paired with partner proteins called RAMPs; in obese mice, losing RAMP1 and RAMP3 blunted cagrilintide's effect on weight 4, while eloralintide, in Lilly's own assays, preferred the human AMY1 receptor 12-fold over the calcitonin receptor 5.
The first amylin drug: pramlintide
Pramlintide High, sold as Symlin, was approved in the US on March 16, 2005 6, as an addition to mealtime insulin in type 1 and type 2 diabetes 1. In a year-long trial in 538 insulin-treated people with type 2 diabetes, HbA1c fell by 0.9% and 1.0% at 13 weeks on the two higher doses but by 0.6% at 52 weeks on the highest, without more insulin or severe hypoglycaemia; weight fell on every dose, and nausea was the most common side effect 7.
It was never approved for weight loss, and Drugs@FDA now lists every Symlin product as discontinued 6.
Cagrilintide and CagriSema (Novo Nordisk)
Cagrilintide Medium is Novo Nordisk's weekly amylin analogue. In a 26-week phase 2 dose-finding trial in 706 adults, weekly doses of 0.3 to 4.5 mg reduced weight by 6.0% to 10.8% against 3.0% on placebo, and the 4.5 mg dose beat liraglutide 3.0 mg, 10.8% against 9.0%; gastrointestinal events affected 41% to 63% against 32% on placebo; Novo Nordisk funded the trial 8.
Novo's main bet is the combination with semaglutide, CagriSema. In REDEFINE 1, 3,417 adults without diabetes who had obesity, or overweight with at least one obesity-related complication, lost 20.4% of their weight over 68 weeks against 3.0% on placebo, and gastrointestinal events affected 79.6% against 39.9%, mostly transient and mild to moderate 9. In REDEFINE 2, in 1,206 adults with type 2 diabetes and a body-mass index of 27 or more, the loss was 13.7% against 3.4% 10. Both trials were funded by Novo Nordisk.
Novo Nordisk says it submitted CagriSema to the FDA in December 2025, based on REDEFINE 1 and 2, and expects a decision by late 2026; in the same February 2026 filing it reported that in REDEFINE 4, an open-label 84-week trial in 809 people, CagriSema did not meet its goal of proving non-inferiority to Lilly's tirzepatide 15 mg (23.0% against 25.5% weight loss, company figures not yet peer-reviewed) 11. FDA's list of 2026 novel drug approvals, current as of October 20, 2026, does not include it 12.
Petrelintide (Zealand Pharma)
Petrelintide Medium is Zealand Pharma's weekly amylin analogue. Its phase 2 trial, ZUPREME 1, randomized adults with obesity, or overweight with high blood pressure or abnormal blood lipids, to weekly petrelintide or placebo. At the primary endpoint, 28 weeks, weight fell 7.9% to 9.8% across five doses against 1.7% on placebo, and the three highest doses performed about the same; weight kept falling to week 42, by up to 10.7%. Nausea affected 20% against 6% on placebo. Zealand Pharma funded the trial 13.
Eloralintide and EloraTZP (Eli Lilly)
Eloralintide Medium is Lilly's weekly amylin agonist. In a 12-week phase 1 trial run by Lilly in 100 people with obesity or overweight, started at the full dose without escalation, mean weight loss ranged from 2.6% to 11.3% across the dose groups 14. Its phase 2 trial enrolled 263 adults at 46 US centres with obesity or overweight and at least one weight-related condition, and no type 2 diabetes. After 48 weeks, weight fell 9%, 12%, 18% and 20% on fixed doses of 1, 3, 6 and 9 mg, 20% when escalated from 6 to 9 mg and 16% from 3 to 9 mg, against 0.4% on placebo. Nausea ranged from 11% to 64% across the groups against 14% on placebo, and fatigue reached 43% and 46% in the two 9 mg groups against 12%; Lilly funded the trial 15.
Lilly has moved eloralintide into five phase 3 trials, the ENLIGHTEN program; each is once weekly, double-blind and placebo-controlled, with the percentage change in body weight at week 64 as the primary endpoint 16. It is also being paired with tirzepatide as EloraTZP, and two phase 3 trials of the combination were registered but not yet recruiting on October 27, 2026 16. Our eloralintide hub follows each trial and readout.
Amycretin (Novo Nordisk)
Amycretin Medium is different in kind: one molecule that acts on both the GLP-1 receptor and amylin receptors, tested as a weekly injection and as a daily tablet. In a phase 1b/2a trial of weekly injections in 125 adults, weight changed by -24.3% against -1.1% on placebo at the 60 mg dose and by -22.0% against +1.9% at 20 mg after 36 weeks; gastrointestinal events were the most common and mostly mild to moderate, and many participants withdrew 17. In the first trial of the tablet, in 144 adults, adverse events affected 62%, all mild or moderate and more common at higher doses, and half of them were gastrointestinal 18. Both trials were run by Novo Nordisk.
A vial sold online is not the trial drug
None of the four newer drugs is approved in the US for weight loss as of October 27, 2026 1 12. A product sold under one of their names outside a trial is not the drug the trials tested, and our guide to what "research use only" means explains why that label does not make a vial safe or legal to inject.
The trial results above come from supervised trials: in the eloralintide phase 2 trial, doses were given at a fixed level or by planned escalation, and nausea still reached 64% in one group 15.
What to watch
Two events will set the field's direction. The first is the FDA's decision on CagriSema, which would be the first amylin-based drug approved for weight loss, since pramlintide was approved only for diabetes 11 1. The second is the eloralintide phase 3 program, five placebo-controlled trials of an amylin agonist on its own, with primary results at week 64 and primary completion dates in 2028 16.
Frequently asked questions
What is amylin?
A peptide hormone that the pancreas releases with insulin. It slows stomach emptying and holds back glucagon after meals, and drugs that copy it lowered weight and after-meal blood sugar in trials.
Is any amylin drug approved for weight loss?
No, as of October 27, 2026. Pramlintide was approved for diabetes in 2005 and is now listed as discontinued. Novo Nordisk says it submitted CagriSema, cagrilintide combined with semaglutide, to the FDA in December 2025.
How much weight do amylin drugs take off?
Alone, cagrilintide reduced weight by up to 10.8% at 26 weeks, petrelintide by 7.9% to 9.8% at 28 weeks and eloralintide by up to 20% at 48 weeks. CagriSema reached 20.4% at 68 weeks, and amycretin 24.3% at 36 weeks on its highest weekly dose.
What are the side effects of amylin drugs?
Gastrointestinal effects, mostly nausea, were the most common in the trials cited here. In the eloralintide phase 2 trial nausea ranged from 11% to 64% across dose groups, and fatigue reached 46% in one group.
Related on Grey Peptides
Sources
- Grey Peptides encyclopedia entries for amylin, pramlintide, cagrilintide, petrelintide, eloralintide and amycretin: mechanism and approval status. Read October 27, 2026.
- Nyholm, B., et al. (1999). The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism, 48(7), 935-41. PMID: 10421239
- Kruse, T., et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem, 64(15), 11183-11194. PMID: 34288673
- Carvas, A. O., et al. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 118, 105836. PMID: 40609154
- Briere, D. A., et al. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab, 102, 102271. PMID: 41109426
- US FDA. Drugs@FDA (openFDA): SYMLIN (pramlintide), NDA 021332, first approved March 16, 2005; every product's marketing status Discontinued. Re-read October 27, 2026.
- Ratner, R. E., et al. (2002). Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther, 4(1), 51-61. PMID: 12017421
- Lau, D. C. W., et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet, 398(10317), 2160-2172. PMID: 34798060
- Garvey, W. T., et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 393(7), 635-647. PMID: 40544433
- Davies, M. J., et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med, 393(7), 648-659. PMID: 40544432
- Novo Nordisk. Company announcement, February 23, 2026 (Form 6-K filed with the US SEC): REDEFINE 4, open-label phase 3, 809 people with obesity, CagriSema 2.4/2.4 mg vs tirzepatide 15 mg for 84 weeks, 23.0% vs 25.5% (efficacy estimand), non-inferiority not achieved; FDA submission in December 2025 based on REDEFINE 1 and 2, decision expected by late 2026. A company release, not peer-reviewed; read October 27, 2026; cited without a link.
- US FDA. Novel Drug Approvals for 2026. Content current as of October 20, 2026; read October 27, 2026. FDA
- Garvey, W. T., et al. (2026). Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol, . PMID: 42810355
- Bhattachar, S., et al. (2026). Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab, 28(4), 2651-2660. PMID: 41559929
- Billings, L. K., et al. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, 406(10520), 2631-2643. PMID: 41207310
- ClinicalTrials.gov. Registry records for the eloralintide (LY3841136) ENLIGHTEN phase 3 program (NCT07282600, NCT07321886, NCT07353931, NCT07369011, NCT07392190), the EloraTZP phase 2b trial NCT06603571 and the eloralintide-tirzepatide phase 3 trials NCT07881432 and NCT07881458; re-read October 27, 2026.
- Dahl, K., et al. (2025). Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet, 406(10499), 149-162. PMID: 40550231
- Gasiorek, A., et al. (2025). Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet, 406(10499), 135-148. PMID: 40550229
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead